- Home
- SCNX vs AYTU Comparison
SCNX vs AYTU Comparison
Compare SCNX & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCNX
- AYTU
- Stock Information
- Founded
- SCNX 2010
- AYTU N/A
- Country
- SCNX United States
- AYTU United States
- Employees
- SCNX N/A
- AYTU N/A
- Industry
- SCNX Other Pharmaceuticals
- AYTU Biotechnology: Pharmaceutical Preparations
- Sector
- SCNX Health Care
- AYTU Health Care
- Exchange
- SCNX Nasdaq
- AYTU Nasdaq
- Market Cap
- SCNX 21.2M
- AYTU 18.8M
- IPO Year
- SCNX 2020
- AYTU N/A
- Fundamental
- Price
- SCNX $0.69
- AYTU $2.32
- Analyst Decision
- SCNX
- AYTU Strong Buy
- Analyst Count
- SCNX 0
- AYTU 3
- Target Price
- SCNX N/A
- AYTU $9.17
- AVG Volume (30 Days)
- SCNX 186.1K
- AYTU 396.7K
- Earning Date
- SCNX 11-05-2025
- AYTU 11-12-2025
- Dividend Yield
- SCNX N/A
- AYTU N/A
- EPS Growth
- SCNX N/A
- AYTU N/A
- EPS
- SCNX N/A
- AYTU N/A
- Revenue
- SCNX $128,202.00
- AYTU $66,382,000.00
- Revenue This Year
- SCNX N/A
- AYTU N/A
- Revenue Next Year
- SCNX N/A
- AYTU $19.03
- P/E Ratio
- SCNX N/A
- AYTU N/A
- Revenue Growth
- SCNX N/A
- AYTU 1.84
- 52 Week Low
- SCNX $0.67
- AYTU $0.95
- 52 Week High
- SCNX $9.55
- AYTU $2.82
- Technical
- Relative Strength Index (RSI)
- SCNX 28.59
- AYTU 53.69
- Support Level
- SCNX $0.67
- AYTU $2.25
- Resistance Level
- SCNX $0.89
- AYTU $2.44
- Average True Range (ATR)
- SCNX 0.08
- AYTU 0.16
- MACD
- SCNX 0.01
- AYTU 0.03
- Stochastic Oscillator
- SCNX 4.14
- AYTU 72.04
About SCNX Scienture Holdings Inc. Common Stock
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.